Inogen Inc
NASDAQ:INGN
Intrinsic Value
Inogen, Inc. engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respirator... [ Read More ]
The intrinsic value of one INGN stock under the Base Case scenario is 20.47 USD. Compared to the current market price of 6.71 USD, Inogen Inc is Undervalued by 67%.
Valuation Backtest
Inogen Inc
Run backtest to discover the historical profit from buying and selling INGN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Inogen Inc
Current Assets | 207.1m |
Cash & Short-Term Investments | 128.5m |
Receivables | 42.9m |
Other Current Assets | 35.7m |
Non-Current Assets | 119.1m |
PP&E | 70.7m |
Intangibles | 44.6m |
Other Non-Current Assets | 3.8m |
Current Liabilities | 72.5m |
Accounts Payable | 23.5m |
Accrued Liabilities | 21.4m |
Other Current Liabilities | 27.6m |
Non-Current Liabilities | 48.9m |
Other Non-Current Liabilities | 48.9m |
Earnings Waterfall
Inogen Inc
Revenue
|
315.7m
USD
|
Cost of Revenue
|
-189m
USD
|
Gross Profit
|
126.7m
USD
|
Operating Expenses
|
-203.2m
USD
|
Operating Income
|
-76.5m
USD
|
Other Expenses
|
-26m
USD
|
Net Income
|
-102.4m
USD
|
Free Cash Flow Analysis
Inogen Inc
INGN Profitability Score
Profitability Due Diligence
Inogen Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Inogen Inc's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
INGN Solvency Score
Solvency Due Diligence
Inogen Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Inogen Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
INGN Price Targets Summary
Inogen Inc
According to Wall Street analysts, the average 1-year price target for INGN is 6.63 USD with a low forecast of 6.06 USD and a high forecast of 7.35 USD.
Ownership
INGN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
INGN Price
Inogen Inc
Average Annual Return | -29.39% |
Standard Deviation of Annual Returns | 10.95% |
Max Drawdown | -96% |
Market Capitalization | 156.3m USD |
Shares Outstanding | 23 330 000 |
Percentage of Shares Shorted | 10.2% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Inogen, Inc. engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company is headquartered in Goleta, California and currently employs 1,021 full-time employees. The company went IPO on 2014-02-14. The firm primarily develops, manufactures, and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen with a single battery and can be plugged into a power outlet as needed. All of its Inogen One systems are equipped with Intelligent Delivery Technology, a form of pulse-dose technology, from which the patient receives a bolus of oxygen upon inhalation. The company has also launched Inogen Connect, a wireless connectivity platform for the Inogen One G4 and Inogen One G5 (portable oxygen concentrators) consisting of a front-end mobile application for use by long-term oxygen therapy users and a back-end database portal for use by homecare providers.
Contact
IPO
Employees
Officers
The intrinsic value of one INGN stock under the Base Case scenario is 20.47 USD.
Compared to the current market price of 6.71 USD, Inogen Inc is Undervalued by 67%.